Supernus files application for apomorphine infusion pump for Parkinson’s

Supernus Pharmaceuticals (NASDAQ:SUPN) has submitted a marketing application with the FDA seeking approval for apomorphine infusion pump (SPN-830) for the continuous treatment of ON-OFF episodes in Parkinson’s disease who have failed two treatments.

“SPN-830, if approved by the FDA, would offer patients a less invasive and a convenient option in the form of a continuous subcutaneous infusion of apomorphine.” said Jack Khattar, President and CEO

https://seekingalpha.com/news/3613628-supernus-files-us-marketing-application-for-apomorphine-infusion-pump-for-parkinson-s